All In Biotech

Drug Trial Radar · NCT05355298

ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

May 31, 2022

Primary completion

Feb 1, 2027

Study completion Feb 1, 2027

Sponsor

Lead sponsor
Amplia Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
May 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line patients with unresectable or metastatic pancreatic cancer. Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Part B will determine the efficacy of the AMP945 regimen at the RP2D, and will be run as a Simon Two-stage design; Stage 1 will enrol 26 participants. If ≤5 of the 26 participants show an objective response, then recruitment will be paused and a detailed analysis of futility will be performed. If the study is deemed futile, recruitment will cease. If the study is determined to be not futile or \>5 of the 26 participants show an objective response, recruitment will continue, and an additional 24 participants will be enrolled in Stage 2.

Conditions

  • Pancreatic Cancer
  • PDAC
  • Pancreatic Ductal Adenocarcinoma

Interventions

  • AMP945 ascending dosesDrug

    Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.

  • AMP945 RP2DDrug

    Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of StudyTime frame: From first dose of study drug to end of study, an expected average of 6 months
  2. Part A: Determination of RP2DTime frame: After Cycle 1 (28 days) for each Part A cohort
  3. Part B: efficacy of AMP945Time frame: Imaging every 56 days per participant, with an expected average duration of 6 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • GenesisCare

    St Leonards, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Gallipolli Medical Research Foundation

    Greenslopes, Queensland, Australia

  • Epworth Healthcare

    Box Hill, Victoria, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Epworth Healthcare

    Richmond, Victoria, Australia

  • Western Health

    St Albans, Victoria, Australia

  • National Cancer Centre

    Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

  • Severence Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Samsung Medical Centre

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.